key: cord-0869152-4jqym656
authors: Castro, M. V.; Santos, K. S.; Apostolico, J. S.; Fernandes, E. R.; Almeida, R. R.; Levin, G.; Magawa, J. Y.; Nunes, J. P. S.; Bruni, M.; Yamamoto, M. M.; Lima, A. C.; Silva, M. V. R.; Matos, L. R. B.; Coria, V. R.; Castelli, E. C.; Scliar, M. O.; Kuramoto, A.; Bruno, F. R.; Jacintho, L. C.; Nunes, K.; Wang, J. Y. T.; Coelho, V. P.; Mitne Neto, M.; Maciel, R. M. B.; Naslavsky, M. S.; Passos-Bueno, M. R.; Boscardin, S. B.; Rosa, D. S.; Kalil, J.; Zatz, M.; Cunha-Neto, E.
title: Monozygotic twins discordant for severe clinical recurrence of COVID-19 show drastically distinct T cell responses to SARS-Cov-2
date: 2021-03-28
journal: nan
DOI: 10.1101/2021.03.26.21253645
sha: 5922755982e49a7a63467fb092657e23d1f3023c
doc_id: 869152
cord_uid: 4jqym656

Background. Clinical recurrence of COVID-19 in convalescent patients has been reported, which immune mechanisms have not been thoroughly investigated. Presence of neutralizing antibodies suggests other types of immune response are involved. Methods. We assessed the innate type I/III IFN response, T cell responses to SARS-CoV-2 with IFN{gamma} ELISPOT, binding and neutralizing antibody assays, in two monozygotic twin pairs with one COVID-19 recurrence case. Results. In pair 1, four months after a first mild episode of infection for both siblings, one displayed severe clinical recurrence of COVID-19. Twin pair 2 of siblings underwent non-recurring asymptomatic infection. All fours individuals presented similar overall responses, except for remarkably difference found in specific cellular responses. Recurring sibling presented a reduced number of recognized T cell epitopes as compared to the other three including her non-recurring sibling. Conclusions. Our results suggest that an effective SARS-CoV-2-specific T cell immune response is key for complete viral control and avoidance of clinical recurrence of COVID-19. Besides, adaptive immunity can be distinct in MZ twins. Given the rising concern about SARS-CoV-2 variants that evade neutralizing antibodies elicited by vaccination or infection, our study stresses the importance of T cell responses in protection against recurrence/reinfection.

binding and neutralizing antibody assays, in two monozygotic twin pairs with one COVID-19 recurrence case. Results. In pair 1, four months after a first mild episode of infection for both siblings, one displayed severe clinical recurrence of COVID-19. Twin pair 2 of siblings underwent non-recurring asymptomatic infection. All fours individuals presented similar overall responses, except for remarkably difference found in specific cellular responses.

Recurring sibling presented a reduced number of recognized T cell epitopes as compared to the other three including her non-recurring sibling. Conclusions. Our results suggest that an effective SARS-CoV-2-specific T cell immune response is key for complete viral control and avoidance of clinical recurrence of COVID-19. Besides, adaptive immunity can be distinct in MZ twins. Given the rising concern about SARS-CoV-2 variants that evade neutralizing antibodies elicited by vaccination or infection, our study stresses the importance of T cell responses in protection against recurrence/reinfection. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 28, 2021. ; https://doi.org/10.1101/2021.03.26.21253645 doi: medRxiv preprint Keywords: COVID-19 recurrence; SARS-CoV-2 reinfection; health care worker; Immune response; Monozygotic Twins.

Coronavirus SARS-Cov2, the causative agent of COVID-19 severe acute respiratory syndrome, has caused the most critical public health crisis in the last 100 years (1) . Clinical recurrence of PCR-confirmed COVID-19 in persons with previous COVID-19 infection has been increasingly reported. This has been attributed to a viral relapse in a host that failed to completely eradicate the virus or to reinfection with a different viral genome (2, 3) . The involvement of innate/Type I/III interferon (IFN) response as well as the specific antibody and T cell responses is well established in the protection against SARS-CoV-2 (4). However, the immune mechanisms underlying reinfection/virus relapse are still mostly unexplored.

Investigation of anti-SARS-CoV-2 immunity in clinical recurrence/reinfection cases have been only directed to the humoral response. COVID-19 reinfection can occur both in the presence or absence of binding (5) or neutralizing antibodies (3, (6) (7) (8) (9) . This suggests that additional immune responses apart from neutralizing antibodies may be involved in control of reinfection and recurrence. Investigation of COVID-19 reinfection/recurrence can thus provide key information regarding immune protection mechanisms and guide vaccine studies

We present a case of monozygotic twins who acquired mild COVID-19 early in 2020 and only one of them-who is a health care worker-presented recurrence four months after initial infection. In order to investigate the underlying immune mechanisms, we performed a comprehensive assessment of innate and adaptive immunity. In addition to binding and neutralizing antibody assays, we assessed the innate type I/III IFN response kinetics after TLR3 stimulation and the T cell response to SARS-CoV-2 synthetic peptides with the IFN-. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 28, 2021. ; https://doi.org/10.1101/2021.03.26.21253645 doi: medRxiv preprint gamma ELISPOT assay. A second pair of monozygotic twins with concordant asymptomatic infection after exposure to COVID-19 symptomatic parents was also studied as a control.

The study was approved by the Committee for Ethics in Research of the Institute of Biosciences at the University of São Paulo (CAAE 34786620.2.0000.5464) and all participants (or their parents) provided a written consent.

Participants were selected based on their clinical history of SARS-CoV-2 infection.

Clinical data were collected in an interview and are detailed in the Supplementary Material.

Participants were followed up for 6-10 months after COVID clinical symptoms and blood samples were collected on July 2020 and January 2021 for Twin pair 1 and 2, respectively.

PBMCs were isolated by density-gradient centrifugation using Ficoll-Paque and stored in liquid nitrogen until use. Sera were processed and kept frozen at -80 o C until use.

Cryopreserved cells were thawn and stimulated with 1µg/ml of Poly I:C HMW (Invivogen) for 1, 4 and 8h. Negative controls were incubated with R10 medium alone. Total RNA was extracted using the RNeasy Mini kit (Qiagen, Germany) and cDNA was prepared using the Superscript II Reverse Transcriptase (Thermofisher, USA), according to the manufacturer's instructions. Real-time PCR was performed using the Power SYBR Green Master Mix (Thermofisher, USA) on a QuantStudio 12K flex (Applied Biosystems, USA).

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) Values were determined as optical density (OD) minus blank and cutoff was determined as blank+ 3x standard deviation.

The pseudovirus neutralization assay was performed exactly as described previously (11).

HT1080 expressing ACE2 cells (HT1080/ACE2) and plasmids HIV-1NLΔEnv-NanoLuc and pSARS-CoV-2-SΔ19 were kindly provided by Dr. Paul D. Bieniasz (The Rockefeller University). Briefly, 104 HT1080/ACE2 were plated in 96-well plates and maintained at 37°C, 5% CO2 for 24hs. The pseudovirus was incubated in duplicate with serial dilutions of . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 28, 2021. ; https://doi.org/10.1101/2021.03.26.21253645 doi: medRxiv preprint 6 the samples for 1h at 37°C. After 48 hours of incubation at 5% CO2 at 37°C, wells were washed, and cells were lysed with Lysis Buffer (Promega). Luciferase substrate (Promega) was added to each well, and the plate read at a GlowMax luminometer (Promega). 50% inhibitory dilution (IC50) was calculated using Prism software (v7.0, GraphPad) after subtraction of the background RLUs in the control wells (cells only).

ELISPOT against a set of 20 CD4+ and 26 CD8+ T cell epitopes from 13 distinct SARS-CoV-2 proteins with high HLA allelic population coverage. We identified and synthesized the CD4+ T cell epitopes by scanning the whole proteome in SARS-CoV-2 reference genome (RefSeq: NC_045512.2) using the promiscuous HLA-DR binding peptide approach (12). The chosen CD8+ T cell epitopes were known to bind stably (www.immunitrack.com) or to be directly recognized (13) in the context of the 10 most frequent HLA class I alleles.

The world population coverage of HLAs predicted to bind to the 20 CD4+ T cell epitopes and 26 CD8+ T cell epitopes was 99.6%, and 94%, respectively, according to the IEDB epitope database (14) . Peptide sequences are listed in Supplementary Table 2 .

Cryopreserved PBMC were thawed and rested overnight in R10 medium (RPMI is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 28, 2021. ; https://doi.org/10.1101/2021.03.26.21253645 doi: medRxiv preprint 7 ionomycin (50 ng/mL and 1 ug/mL, respectively) and developed with AEC substrate. Spots were counted using an AID ELISpot Reader System (Autoimmun Diagnostika GmbH). The number of IFNγ producing cells/10 6 PBMC for each peptide was calculated after subtracting the values of control wells (R10 medium alone) for each subject. The cutoff value (105 IFNγ producing cells/10 6 PBMC) was established as the average + 3 standard deviations of test results of the 46 peptides on cryopreserved PBMC from 19 pre-pandemic Brazilian healthy control subjects (data not shown).

Whole-exome sequencing was performed on peripheral blood DNA in Illumina NovaSeq platform at HUG-CELL facilities. Sequencing data was analyzed following bwa-mem and GATK Best Practices workflow, quality control and annotation was performed as previously described (15) . HLA genes were realigned and called using HLA-mapper, which reduces mapping and calling errors (16).

Demographical data and HLA, A, B, C and DR alleles of each of the twin pairs are compiled in Table 1 . Clinical symptoms of COVID-19, laboratory results and dates of specific immunological tests for both twin pairs are summarized in timelines (Figure 1) . The volunteers of the present study were identified as V01, V02 (siblings of twin pair 1), V03 and V04 (siblings of twin pair 2). For twin pair 1, initial COVID-19 symptoms were mild in both siblings (V01 in February and V02 in April). Both tested positive for anti-SARS-CoV-2 IgG in mid-May 2020. Four months after her first COVID-19-episode, V01 displayed a severe . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Figure 2A) . Both twins displayed IgG against the Spike protein, with higher levels for V01 than V02 while the twin pair 2 presented anti-Spike and anti-NP IgG. Likewise, neutralizing antibodies (nAb) titers were around 1:500 for V01 and just below negative control for V02.

For twin pair 2, nAb levels were similar to those of V01 ( Figure 2B) . IgG antibodies against the RBD of the four main circulating endemic coronaviruses, NL63, 229E, HKU1, OC43

were similar for all 4 cases, displaying antibodies for 3 out of 4 tested coronaviruses. The antibody profiles to human endemic coronaviruses were virtually identical in both twins V01 and V02 (Figure 2C) .

To investigate the kinetics of innate type I/III IFN responses, we stimulated PBMC with TLR stimulus (double-stranded RNA Poly I:C). We observed early (1h) and high (FC>10) mRNA expression of at least one of the four IFNs tested in all four cases. In twin siblings from pair 1, V01 expressed high IFNB1, and V02 expressed high IFNA2 and IFNL3 ( Figure   3A ). In twin pair 2, V03 expressed high IFNA2 and INFL2, while V04 expressed high IFNB1 ( Figure 3B) . Kinetics of Type I/type III IFNs was variable in later time points. Expression of ISGs was nearly identical within each twin pair, presenting an identical pattern of IFIT3, IFITM1 and IRF7 in twin pair 1 while a lower, concordant response was observed for pair 2 ( Figures 3E-H) .

To assess the T cell responses to SARS-CoV-2 T cell epitopes, we performed IFNγ ELISPOT assays on PBMC samples (see timelines in Figure 1 ). The recurrent case V01 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 28, 2021. ; https://doi.org/10.1101/2021.03.26.21253645 doi: medRxiv preprint 9 recognized only 3 out of 20 CD4+ T cell epitopes (15%) while her sibling recognized 17 CD4+ T cell epitopes (85%; P<0.0001, Fisher Exact Test) ( Figure 4A) . Furthermore, V01 recognized only 4 CD8+ T cell epitopes (15%), while her sibling recognized 19 out of the 26 CD8+ T cell epitopes (73%; P<0.0001, Fisher Exact Test) (Figure 4B) . Both twin siblings V03 and V04 recognized >70% of CD4+ and CD8+ epitopes (20 and 14 out of 20 CD4+ T cell epitopes and 26 and 21 out of 26 CD8+ T cell epitopes, respectively) (Figures 4A and   4B ). These results indicate that the twin with COVID-19 recurrence showed a drastically reduced breadth (number of recognized epitopes) of both CD4+ and CD8+ SARS-CoV-2 T cell epitopes as compared with her non-recurrent sibling and also the second MZ twin pair.

Here we describe a comprehensive assessment of innate and adaptive immune response against SARS-CoV-2 in two pairs of monozygotic twins, including a case of severe COVID-19 recurrence in one of two twin, a health care worker. We found that the only immune parameter that was substantially lower in the COVID-19 recurrence case as compared to her twin sibling and a second pair of MZ twins was the breadth (number of recognized epitopes) of the CD4+ and CD8+ T cell responses. To our knowledge, this is the first report of innate and T cell immune responses in the context of COVID-19 recurrence and reinfection. Of note, there were also fluctuations in some other immune parameters within each MZ twin pair.

Innate Type I/III IFN responses are the first line of cellular defense against RNA viruses.

viruses due to viral-encoded proteins that dampen such responses (4) . An immune response characterized by a weak, delayed production of Type I/III interferons contributes to severe forms of the disease (17) . The finding that all four tested patients including the COVID-19 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 28, 2021. ; https://doi.org/10.1101/2021.03.26.21253645 doi: medRxiv preprint recurrence case presented an early, strong type I/III IFN response indicates that recurrence was not associated with failure in the innate IFN response.

responses. Memory responses to secondary exposure to pathogen limit or prevent reinfection (5) . Immunological investigation of COVID-19 recurrence and reinfection has been so far limited to antibody reactivity profiles. In a recent review of 16 reinfection cases ocurring 19-142 days after the first infection episode, 10 reported anti-SARS-CoV-2IgG testing, 6 of which displayed positive serology at the time of second infection; reinfections occurred in patients with all degrees of severity in the primary infection, but 75% of the reinfections were asymptomatic or mild (5) . Neutralizing antibodies (nAb) were detected at the time of reinfection in three case reports (3, 6, 7), while only one case reported reinfection in the absence of detectable nAb (8) suggesting that responses beyond neutralizing antibodies are important to control reinfection. In our study, reinfected case V01 presented nAb 6 weeks after COVID-19 recurrence. Although we cannot ensure that neutralizing antibodies were present earlier when recurrence occurred, increased levels of anti-SARS-CoV-2 IgG were detectable at hospital admission indicating that COVID-19 recurrence boosted IgG levels, which is in line with literature reports (5) .

Our finding that the CD4+ and CD8+ T cell responses of the COVID-19 recurrence case had a drastically reduced breadth 4 months after hospital discharge is indicative of a low SARS-CoV-2-specific T cell response. This is in contrast with the finding that hospitalized patients display a larger breadth of CD4+ T cell responses than outpatients (18) . Given the importance of T cell responses associated with COVID-19 infection (19), a dampened CD4+ T cell response can have important consequences for many aspects of anti-SARS-COV-2 immunity. Asymptomatic and mild cases of CoVID-19 are correlated with specific CD4+ and CD8+ T cell responses, but not with IgG or neutralizing antibody, suggesting that T cells are . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is unlikely that the reduced T cell responses observed in V01 are due the absence of HLA presentation to T cells, since her MZ twin V02 carrying the same HLA alleles displayed a broad recognition profile. Also, it is not likely that the contrasting T cell responses observed between the two siblings is a result of previous exposure to cross-reacting viruses (23), since their IgG profile against human endemic coronaviruses' RBD was nearly identical.

Our study has limitations. We report observations for only one case of COVID-19 recurrence and cannot ensure that our findings are common in COVID-19 recurrence. We cannot conclude whether this recurrence event is a bona fide reinfection or a viral relapse in a chronic carrier since we did not genotype the SARS-CoV-2 virus. Most reinfection episodes were reported to be asymptomatic or mild (5) . However, the 4-month interval between the two events in an exposed health care worker with a more severe clinical presentation is more suggestive of reinfection due to re-exposure than of a viral relapse.

In short, our results suggest that the failure in inducing a broad T cell response might have enhanced susceptibility to COVID-19 recurrence in the reported case. Our data may support a prime role for T cells in protection against reinfection. Given the increased concern that SARS-CoV-2 variants escaping antibody neutralization could give rise to a massive raise in reinfection (24, 25) , our case stresses the importance of T cell immune responses in protection against reinfection. This is in line with the reported lack of deleterious effect of . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

The authors declare that there is no conflict of interests regarding the publication of this work.

M. V. C. and K. S. S. contributed equally to this work as co-first authors. E. C. N., J.K., and M. Z. contributed equally to this work as principal investigators. All authors contributed significantly to this work.

The authors are extremely grateful for the participation and collaboration of the four twins and their families, the nurses for samples collection, the technical team and the Fleury Laboratory for serology tests. Special thanks to JBS. S.A. for the additional funding.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 28, 2021. ; https://doi.org/10.1101/2021.03.26.21253645 doi: medRxiv preprint

COVID-19 become the next neglected tropical disease? PLOS Neglected Tropical Diseases

Clinical recurrences of COVID-19 symptoms after recovery: Viral relapse, reinfection or inflammatory rebound? The Journal of infection

Evidence of Severe Acute Respiratory Syndrome Coronavirus 2 Reinfection After Recovery from Mild Coronavirus Disease

Adaptive immunity to SARS-CoV-2 and COVID-19

is a consultant for Avalia. LJI has filed for patent protection for various aspects of T cell epitope and vaccine design work

The Importance and Challenges of Identifying SARS-CoV-2 Reinfections

genome that are frequently recognized by HIV-1 infected patients

A Sequence Homology and Bioinformatic Approach Can Predict Candidate Targets for Immune Responses to SARS-CoV-2. Cell host & microbe

The Immune Epitope Database (IEDB): 2018 update. Nucleic acids research

Hla-mapper: An application to optimize the mapping of HLA sequences produced by massively parallel sequencing procedures

Unsuspected intraspecific variability in the toxin production, growth and morphology of the dinoflagellate Alexandrium pacificum R.W. Litaker (Group IV) blooming in a South Western Mediterranean marine ecosystem, Annaba Bay (Algeria)

T cell and antibody functional correlates of severe COVID-19. medRxiv : the preprint server for health sciences

International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19

Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19

Intrafamilial Exposure to SARS-CoV-2 Associated with Cellular Immune Response without

Emerging infectious diseases

Airway Memory CD4(+) T Cells Mediate Protective Immunity against Emerging Respiratory Coronaviruses. Immunity

Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans

SARS-CoV-2 Viral Variants-Tackling a Moving Target

Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7. Nature

Symptomatic SARS-CoV-2 reinfection of a health care worker in a Belgian nosocomial . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 28, 2021. ; https://doi.org/10.1101/2021.03.26.21253645 doi: medRxiv preprint It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted March 28, 2021. ; https://doi.org/10.1101/2021.03.26.21253645 doi: medRxiv preprint